STAMFORD, Conn., May 31, 2018 /PRNewswire-PRWeb/ -- Global Lyme Alliance (GLA), the leading
"Our 2017-18 grantees are truly some of the most talented researchers in the field today," said Timothy J. Sellati, Ph.D., GLA's Chief Scientific Officer. "Results from the studies we are funding—which include several 'firsts' for GLA—will significantly advance our basic understanding of Lyme and other tick-borne diseases, improve diagnostics, and expand treatment options for physicians, while offering hope to the millions who suffer from Lyme disease."
For the first time, GLA is funding pediatrics-specific projects that could have a major impact on the long-term health of children and their mothers. One study is being conducted by Lise Nigrovic, M.D., Ph.D., a pediatrician at Boston Children's Hospital and associate professor of pediatrics and emergency medicine at Harvard Medical School. Dr. Nigrovic received a grant award to expand and continue building her existing pediatric Lyme disease biobank to collect well-curated blood and tissue samples from children tested for Lyme.
GLA's second pediatrics-specific study investigates the role Borrelia burgdorferi, the pathogen that causes Lyme, might play in damaging the fetus or impairing nervous system development, function, and behavior when a pregnant woman contracts Lyme disease. This study is being conducted by Catherine Brissette, Ph.D., associate professor of biomedical sciences at the University of North Dakota.
GLA is also funding a study focused on whether essential oils—aromatic compounds derived from plants—can treat drug resistant and persistent Lyme disease in humans. Intriguing preliminary findings reported by Ying Zhang, M.D., Ph.D., a professor of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health, demonstrated that several essential oils had excellent in-vitro activity against B.burgdorferi persisters.
Other important areas of focus among the current grantees include the impact of Borrelia burgdorferi on the immune system, treatment of chronic Lyme disease, the role of individual patient genetics in response to Lyme disease, and Lyme diagnostics.
"With our new grants, Global Lyme Alliance remains at the forefront of discovery and innovation," said Scott Santarella, GLA's CEO. "Our investments in Lyme and tick-borne disease research are particularly important today since federal funding for Lyme research is miniscule. This, unfortunately, hamstrings researchers and slows scientific progress."
Those awarded 2017-18 GLA-funded research grants include:
The researchers were selected following a rigorous process using guidelines established by the National Institutes of Health (NIH). Each proposal was evaluated by GLA's Scientific Advisory Board and met the same scientific standards that the NIH applies to its own research grant review process. The resulting 2018 grant awards represent projects judged to have exceptional prospects of delivering measurable advances.
Lyme disease is a growing epidemic with more than 329,000 reported new cases each year in the United States, according to the Centers for Disease Control and Prevention. However, there are presently no accurate diagnostic tests, no standard treatment and no cure. Some 10 to 20% of individuals with Lyme end up with long-term health problems, proven by GLA-funded research.
GLA is now accepting grant proposals for its 2018-19 grant funding cycle. All applications are due by August 1, 2018 midnight EST. Award decisions will be announced in January 2019. For more information, go to GLA.org.
ABOUT GLOBAL LYME ALLIANCE Global Lyme Alliance (GLA) is the leading 501(c)(3) dedicated to conquering Lyme disease through research, education and awareness. GLA has gained national prominence for funding the most urgent and promising research in the field, while expanding education and awareness programs for the general public and physicians. Learn more at GLA.org.
SOURCE Global Lyme Alliance
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All